News from the "5th international meeting on inflammatory bowel diseases" CAPRI 2010

Journal of Crohn's and Colitis

Volumn 4, Issue 6, 2010, Pages 690-702

  Latella, Giovanni ^a   Fiocchi, Claudio ^b   Caprili, Renzo ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b LERNER RESEARCH INSTITUTE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Environment; Genetics; Gut flora; Immunomodulation; Inflammatory bowel diseases; Medical therapy

Indexed keywords

ADAPTIVE IMMUNITY; AUTOPHAGY; BIOLOGICAL THERAPY; CROHN DISEASE; ENDOPLASMIC RETICULUM STRESS; ENTERITIS; ENVIRONMENTAL FACTOR; ENVIRONMENTAL STRESS; EPIGENETICS; EPSTEIN BARR VIRUS; GENE LOCUS; GENETIC ASSOCIATION; HEALTH CARE DELIVERY; HEREDITY; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; INTESTINE FLORA; LYMPHOMA; MEDICAL RESEARCH; METABOLOME; METAGENOME; MIGRATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

ADAPTIVE IMMUNITY; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 78649506169     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.08.002     Document Type: Review

References (88)

1. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., Ollendorf D., Bousvaros A., Grand R.J., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007, 5:1424-1429.
2. Thia K.T., Loftus E.V., Sandborn W.J., Yang S.K. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008, 103:3167-3187.
3. de Silva H.J., de Silva N.R., de Silva A.P., Jewell D.P. Emergence of inflammatory bowel disease 'beyond the West': do prosperity and improved hygiene have a role?. Trans R Soc Trop Med Hyg 2008, 102:857-860.
4. Bernstein C.N., Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 2008, 57:1185-1191.
5. Shivananda S., Lennard-Jones J., Logan R., Fear N., Price A., Carpenter L., et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996, 39:690-697.
6. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002, 347:911-920.
7. Basu D., Lopez I., Kulkarni A., Sellin J.H. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol 2005, 100:2254-2261.
8. Chapman-Kiddell C.A., Davies P.S., Gillen L., Radford-Smith G.L. Role of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis 2010, 16:137-151.
9. Cámara R.J., Ziegler R., Begré S., Schoepfer A.M. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. Digestion 2009, 80:129-139. Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) group.
10. Bousquet J., Burney P.G., Zuberbier T., Cauwenberge P.V., Akdis C.A., Bindslev-Jensen C., et al. GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. Allergy 2009, 64:969-977.
11. Martin B., Hirota K., Cua D.J., Stockinger B., Veldhoen M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009, 31:321-330.
12. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453:106-109.
13. Esser C., Rannug A., Stockinger B. The aryl hydrocarbon receptor in immunity. Trends Immunol 2009, 30:447-454.
14. Zhang H., Massey D., Tremelling M., Parkes M. Genetics of inflammatory bowel disease: clues to pathogenesis. Br Med Bull 2008, 87:17-30.
15. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962.
16. McGovern D.P., Gardet A., Törkvist L., Goyette P., Essers J., Taylor K.D., et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010, 42:332-337.
17. Tap J., Mondot S., Levenez F., Pelletier E., Caron C., Furet J.P., et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009, 11:2574-2584.
18. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
19. Sokol H., Seksik P., Furet J.P., Firmesse O., Nion-Larmurier I., Beaugerie L., et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009, 15:1183-1189.
20. Willing B., Halfvarson J., Dicksved J., Rosenquist M., Järnerot G., Engstrand L., et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 2009, 15:653-660.
21. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermúdez-Humarán L.G., Gratadoux J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008, 105:16731-16736.
22. Packey C.D., Sartor R.B. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis 2009, 22:292-301.
23. Ley R.E., Hamady M., Lozupone C., Turnbaugh P.J., Ramey R.R., Bircher J.S., et al. Evolution of mammals and their gut microbes. Science 2008, 320:1647-1651.
24. Salzman N.H., Hung K., Haribhai D., Chu H., Karlsson-Sjöberg J., Amir E., Bos N.A., et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010, 11:76-83.
25. Haller D. Nutrigenomics and IBD: The Intestinal Microbiota at the Cross-road Between Inflammation and Metabolism. J Clin Gastroenterol Jun 8 2010, [Epub ahead of print].
26. Pospisilik J.A., Knauf C., Joza N., Benit P., Orthofer M., Cani P.D., et al. Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell 2007, 131:476-491.
27. Kaser A., Lee A.H., Franke A., Glickman J.N., Zeissig S., Tilg H., et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008, 134:743-756.
28. Kaser A., Martínez-Naves E., Blumberg R.S. Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2010, 26:318-326.
29. Beltrán B., Nos P., Dasí F., Iborra M., Bastida G., Martínez M., et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn's disease. Inflamm Bowel Dis 2010, 16:76-86.
30. Werner T., Hoermannsperger G., Schuemann K., Hoelzlwimmer G., Tsuji S., Haller D. Intestinal epithelial cell proteome from wild-type and TNFDeltaARE/WT mice: effect of iron on the development of chronic ileitis. J Proteome Res 2009, 8:3252-3264.
31. Nakamura T., Furuhashi M., Li P., Cao H., Tuncman G., Sonenberg N., et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010, 140:338-348.
32. Todd D.J., Lee A.H., Glimcher L.H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008, 8:663-674.
33. Kaser A., Blumberg R.S. Endoplasmic reticulum stress and intestinal inflammation. Mucosal Immunol 2010 Jan, 3(1):11-16. Epub 2009 Oct 28. Review.
34. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu Rev Immunol 2010, 28:573-621.
35. Huett A., Goel G., Xavier R.J. A systems biology viewpoint on autophagy in health and disease. Curr Opin Gastroenterol 2010, 26:302-309.
36. Huett A. Xavier RJ.Autophagy at the gut interface: mucosal responses to stress and the consequences for inflammatory bowel diseases. Inflamm Bowel Dis 2010, 16:152-174.
37. Lapaquette P., Glasser A.L., Huett A., Xavier R.J., Darfeuille-Michaud A. Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol 2010, 12:99-113.
38. Cooney R., Baker J., Brain O., Danis B., Pichulik T., Allan P., et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010, 16:90-97.
39. Travassos L.H., Carneiro L.A., Ramjeet M., Hussey S., Kim Y.G., Magalhães J.G., et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010, 11:55-62.
40. Mota L.J., Cornelis G.R. The bacterial injection kit: type III secretion systems. Ann Med 2005, 37:234-249.
41. Huett A., Ng A., Cao Z., Kuballa P., Komatsu M., Daly M.J., Xavier R.J., et al. A novel hybrid yeast-human network analysis reveals an essential role for FNBP1L in antibacterial autophagy. J Immunol 2009, 182:4917-4930.
42. Mariathasan S., Monack D.M. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 2007, 7:31-40.
43. Brodsky I.E., Monack D. NLR-mediated control of inflammasome assembly in the host response against bacterial pathogens. Semin Immunol 2009, 21:199-207.
44. Maloy K.J., Kullberg M.C. IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol 2008, 1:339-349.
45. Rakoff-Nahoum S., Medzhitov R. Innate immune recognition of the indigenous microbial flora. Mucosal Immunol 2008, 1(Suppl 1):S10-S14.
46. Liu K., Victora G.D., Schwickert T.A., Guermonprez P., Meredith M.M., Yao K., et al. In vivo analysis of dendritic cell development and homeostasis. Science 2009, 324:392-397.
47. Bogunovic M., Ginhoux F., Helft J., Shang L., Hashimoto D., Greter M., et al. Origin of the lamina propria dendritic cell network. Immunity 2009, 31:513-525.
48. Xiang X.S., Zhao Y.Z., Li N., Li Q.R., Li J.S. Accumulation of DC in lamina propria induced by FMS-like tyrosine kinase 3 ligand aggravates the intestinal inflammatory response during endotoxemia. Inflammation 2010, 33:34-45.
49. Varol C., Vallon-Eberhard A., Elinav E., Aychek T., Shapira Y., Luche H., et al. Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 2009, 31:502-512.
50. Liu K., Nussenzweig M.C. Origin and development of dendritic cells. Immunol Rev 2010, 234:45-54.
51. Lotze M.T., Zeh H.J., Rubartelli A., Sparvero L.J., Amoscato A.A., Washburn N.R., et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007, 220:60-81.
52. Davé S.H., Tilstra J.S., Matsuoka K., Li F., DeMarco R.A., Beer-Stolz D., et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol 2009, 86:633-643.
53. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010, 28:367-388.
54. Yanai H., Ban T., Wang Z., Choi M.K., Kawamura T., Negishi H., et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462:99-103.
55. Kazama H., Ricci J.E., Herndon J.M., Hoppe G., Green D.R., Ferguson T.A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008, 29:21-32.
56. Rubartelli A., Lotze M.T. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007, 28:429-436.
57. Bjornsson H.T., Fallin M.D., Feinberg A.P. An integrated epigenetic and genetic approach to common human disease. Trends Genet 2004, 20:350-358.
58. Murrell A., Rakyan V.K., Beck S. From genome to epigenome. Hum Mol Genet 2005, 14. Spec No 1:R3-R10.
59. Bäckdahl L., Bushell A., Beck S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell Biol 2009, 41:176-184.
60. Wilson C.B., Rowell E., Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009, 9:91-105.
61. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
62. Zhou L., Lopes J.E., Chong M.M., Ivanov I.I., Min R., Victora G.D., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
63. Ivanov I.I., Frutos Rde L., Manel N., Yoshinaga K., Rifkin D.B., Sartor R.B., et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008, 4:337-349.
64. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
65. Ivanov I.I., Littman D.R. Segmented filamentous bacteria take the stage. Mucosal Immunol 2010, 3:209-212.
66. Ahern P.P., Izcue A., Maloy K.J., Powrie F. The interleukin-23 axis in intestinal inflammation. Immunol Rev 2008, 226:147-159.
67. Izcue A., Coombes J.L., Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009, 27:313-338.
68. Izcue A., Hue S., Buonocore S., Arancibia-Cárcamo C.V., Ahern P.P., Iwakura Y., et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 2008, 28:559-570.
69. Buonocore S., Ahern P.P., Uhlig H.H., Ivanov I.I., Littman D.R., Maloy K.J., et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010, 464:1371-1375.
70. Neurath M.F., Finotto S. Translating inflammatory bowel disease research into clinical medicine. Immunity 2009, 31:357-361.
71. Kanai T., Nemoto Y., Kamada N., Totsuka T., Hisamatsu T., Watanabe M., et al. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. Curr Opin Gastroenterol 2009, 25:306-313.
72. Zenewicz L.A., Antov A., Flavell R.A. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009, 15:199-207.
73. Waldner M.J., Neurath M.F. Novel cytokine-targeted therapies and intestinal inflammation. Curr Opin Pharmacol 2009, 9:702-707.
74. Waldner M.J., Neurath M.F. Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 2009, 31:249-256.
75. Atreya R., Neurath M.F. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets 2008, 9:369-374.
76. Weigmann B., Lehr H.A., Yancopoulos G., Valenzuela D., Murphy A., Stevens S., et al. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med 2008, 205:2099-2110.
77. Mudter J., Amoussina L., Schenk M., Yu J., Brüstle A., Weigmann B., et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest 2008, 118:2415-2426.
78. Mudter J., Yu J., Amoussina L., Weigmann B., Hoffman A., Rücknagel K., et al. IRF4 selectively controls cytokine gene expression in chronic intestinal inflammation. Arch Immunol Ther Exp (Warsz) 2009, 57:369-376.
79. Leppkes M., Becker C., Ivanov I.I., Hirth S., Wirtz S., Neufert C., et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009, 136:257-267.
80. D'Haens G.R., Fedorak R., Lémann M., Feagan B.G., Kamm M.A., Cosnes J., et al. IOIBD Membership. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis 2009, 15:1599-1604.
81. D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007, 56:725-732.
82. Rahier J.F., Yazdanpanah Y., Colombel J.F., Travis S. The European (ECCO) Consensus on infection in IBD: what does it change for the clinician?. Gut 2009, 58:1313-1315.
83. Sokol H., Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut 2009, 58:1427-1436.
84. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lémann M., Cosnes J., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
85. Shale M., Kanfer E., Panaccione R., Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008, 57:1639-1641.
86. Weersma R.K., Stokkers P.C., van Bodegraven A.A., van Hogezand R.A., Verspaget H.W., de Jong D.J., et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009, 58:388-395. Dutch Initiative on Crohn and Colitis (ICC).
87. Zhou L., Chong M.M., Littman D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30:646-655.
88. Lu L.F., Thai T.H., Calado D.P., Chaudhry A., Kubo M., Tanaka K., et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009, 30:80-91.